scholarly journals Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Seong Joon Ahn ◽  
Jeeyun Ahn ◽  
Se Joon Woo ◽  
Kyu Hyung Park
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Initial Dose ◽  
Branch Retinal Vein Occlusion ◽  
Dose Group ◽  
Intravitreal Bevacizumab ◽  
Intravitreal Injections ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Initial Injection

Purpose. To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods. This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection.Results. At month 6, BCVA change from baseline was-0.27±0.28(mean ± standard deviation) logMAR in the PRN group and-0.28±0.20 logMAR in the 3 monthly initial dose group. Mean CRT changes were-204±168in the PRN group and-161±149 μm in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group (1.8±0.8injections) than in the 3 monthly initial dose group (3.4±0.5injections;P<0.001).Conclusions. Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

2009 ◽  
Vol 44 (2) ◽  
pp. 154-159 ◽  
Author(s):  
Amir Ali Ahmadi ◽  
Jean Y. Chuo ◽  
Alexander Banashkevich ◽  
Patrick E. Ma ◽  
David A.L. Maberley
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Vein Occlusion

Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab

2012 ◽  
Vol 56 (2) ◽  
pp. 159-164 ◽  
Author(s):  
Tatsuya Yunoki ◽  
Akio Miyakoshi ◽  
Tomoko Nakamura ◽  
Kazuya Fujita ◽  
Chiharu Fuchizawa ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Injections ◽  
Vein Occlusion

EFFICACY OF COMBINED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE IN PATIENTS WITH NON-RESOLVING MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

2021 ◽  
pp. 48-49
Author(s):  
Haniyaa Mufti ◽  
Syed Tariq Qureshi ◽  
Birjees Hakak
Keyword(s):  
Combination Therapy ◽  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Common Adverse Effect ◽  
Visual Outcome ◽  
Intravitreal Injections ◽  
Therapeutic Effects ◽  
Vein Occlusion

Purpose: To study the effects of combined intravitreal injections of bevacizumab (IVB) and triamcinolone acetonide (IVTA) in patients with non-resolving macular edema (ME) secondary to Branch Retinal Vein Occlusion (BRVO). Methods: In a prospective observational study, 50 pseudophakic eyes of BRVO patients with non-resolving central macular edema who had received more than 3 doses of IVB previously were injected with combination therapy of 1.25 mg/0.05 ml IVB and 4 mg of IVTA and followed up for 6 months with best corrected visual acuity(BCVA), intraocular pressure(IOP) and central macular thickness(CMT) Results: The mean BCVA was logMAR 0.75±0.25 at baseline and 0.65±0.15, 0.48±0.20, and 0.22±0.25 at 6weeks, 3 months and 6 months respectively. Mean CMT at baseline was 668.32±254.66 and 434.43±99.55, 243.22±58.92, and 220.83±42.60 at 6 weeks, 3 months and 6 months respectively. Baseline IOP measured was 16.5±3.1 mmHg which progressed to 19.6±3.4mmHg and 21.4±2.8mmHg at 6 weeks and 3 months respectively and decreased to 17.3±2.2 at 6 months. The most common adverse effect seen was increase in IOP in 24(48%)patients, out of which 3(6%) patients needed to start anti-glaucoma medication (AGM). 3(6%) patients had sub-conjunctival hemorrhage(SCH). Conclusion: The prolonged therapeutic effects of combination therapy leads to outstanding anatomical and visual outcome in non resolving ME due to BRVO, with fewer doses and thus fewer adverse effects.

INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

2018 ◽  
Vol 12 (2) ◽  
pp. 93-96 ◽  
Author(s):  
Gabriel Costa de Andrade ◽  
João Rafael de Oliveira Dias ◽  
André Maia ◽  
Michel Eid Farah ◽  
Somaia Mitne ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Injections ◽  
Vein Occlusion

scholarly journals Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Keiji Inagaki ◽  
Kishiko Ohkoshi ◽  
Sachiko Ohde ◽  
Gautam A. Deshpande ◽  
Nobuyuki Ebihara ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Disease Onset ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Group I ◽  
Group Ii ◽  
Best Corrected Visual Acuity

To assess the efficacy of subthreshold micropulse diode laser photocoagulation (SMDLP) for persistent macular edema secondary to branch retinal vein occlusion (BRVO), including best-corrected visual acuity (BCVA) > 20/40, thirty-two patients (32 eyes) with macular edema secondary to BRVO were treated by SMDLP. After disease onset, all patients had been followed for at least 6 months prior to treatment. Baseline Snellen visual acuity was used to categorize the eyes as BCVA ≤ 20/40 (Group I) or BCVA > 20/40 (Group II). Main outcome measures were reduction in central macular thickness (CMT) in optical coherence tomography (OCT) and BCVA at 6 months. In the total subject-pool at 6 months, BCVA had not changed significantly but CMT was significantly reduced. Group I exhibited no significant change in CMT at 3 months but exhibited significant reductions at 6 and 12 months. Group II exhibited a marginally significant reduction in CMT at 3 months and a significant reduction at 6 months. In patients with persistent macular edema secondary to BRVO, SMDLP appears to control macular edema with minimal retinal damage. Our findings suggest that SMDLP is an effective treatment method for macular edema in BRVO patients with BCVA > 20/40.

Sign in / Sign up

Export Citation Format

Share Document